DEVELOPING A QUADRIVALENT HCV VACCINE
Grant number: 1126379 | Funding period: 2017 - 2019
A vaccine for hepatitis C virus (HCV) is not yet available. Immune responses that are able to protect against infection are possible, making the production of a vaccine a realistic goal. We have produced a unique HCV vaccine and are now poised to test our vaccine in novel humanised animal models. Our research will allow us to determine the immune responses responsible for providing protection against HCV. Our data will be highly significant for future HCV vaccine studies in humans.
Related publications (4)
Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery
D Christiansen, L Earnest-Silveira, B Grubor-Bauk, DK Wijesundara, I Boo, PA Ramsland, E Vincan, HE Drummer, EJ Gowans, J Torresi
The introduction of directly acting antiviral agents (DAAs) has produced significant improvements in the ability to cure chronic h..
Probing and pressing surfaces of hepatitis C virus-like particles
Simon Collett, Joseph Torresi, Linda Earnest-Silveira, Dale Christiansen, Aaron Elbourne, Paul A Ramsland
Hepatitis C virus-like particles (VLPs) are being developed as a quadrivalent vaccine candidate, eliciting both humoral and cellul..
Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine
D Christiansen, L Earnest-Silveira, B Chua, P Meuleman, I Boo, B Grubor-Bauk, DC Jackson, ZY Keck, SKH Foung, HE Drummer, EJ Gowans, J Torresi
The significant public health problem of Hepatitis C virus (HCV) has been partially addressed with the advent of directly acting a..